President Donald Trump met with executives from the pharmaceutical industry Tuesday morning at the White House to discuss ways to lower the exponentially increasing drug prices in the U.S. The stocks of some of these firms are soaring following the meeting.
The president met with the heads of Novartis AG, Merck & Co. Inc., Johnson & Johnson, Celgene Corp., Eli Lilly & Co., and Amgen Inc. Following the meeting, stock values of Merck & Co. Inc., Novartis AG, and Eli Lilly & Co., and Amgen Inc. are all up.
Trump told the executives that “we have to lower drug prices,” increase research and development spending, and massively deregulate the pharmaceutical industry to lower barriers for entry of new drugs to the market. (RELATED: Trump Tells Big Pharma: Drug Prices Must Go Down)
Pricing of pharmaceuticals came into the public spotlight when news broke in August that Mylan, the maker of the life-saving epinephrine injection device EpiPen, raised the price of the EpiPen 461 percent in under a decade.
Send tips to robert@
All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact firstname.lastname@example.org.